Free Trial

Penumbra (PEN) Competitors

Penumbra logo
$249.32 -4.52 (-1.78%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$249.42 +0.10 (+0.04%)
As of 10/17/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PEN vs. LNTH, ITGR, GEHC, PHG, ZBH, SNN, SOLV, STVN, IRTC, and BLCO

Should you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Stevanato Group (STVN), iRhythm Technologies (IRTC), and Bausch + Lomb (BLCO). These companies are all part of the "medical" sector.

Penumbra vs. Its Competitors

Lantheus (NASDAQ:LNTH) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Lantheus had 29 more articles in the media than Penumbra. MarketBeat recorded 43 mentions for Lantheus and 14 mentions for Penumbra. Penumbra's average media sentiment score of 0.25 beat Lantheus' score of 0.07 indicating that Penumbra is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
4 Very Positive mention(s)
2 Positive mention(s)
28 Neutral mention(s)
5 Negative mention(s)
1 Very Negative mention(s)
Neutral
Penumbra
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lantheus has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Lantheus currently has a consensus price target of $74.50, indicating a potential upside of 33.99%. Penumbra has a consensus price target of $302.81, indicating a potential upside of 21.45%. Given Lantheus' higher possible upside, equities analysts clearly believe Lantheus is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Penumbra
0 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.89

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.53B2.46$312.44M$3.7614.79
Penumbra$1.28B7.60$14.01M$3.7666.31

Lantheus has a net margin of 17.82% compared to Penumbra's net margin of 11.54%. Lantheus' return on equity of 34.06% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus17.82% 34.06% 19.10%
Penumbra 11.54%11.55%8.76%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.5% of Lantheus shares are owned by company insiders. Comparatively, 4.2% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Lantheus and Penumbra tied by winning 8 of the 16 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PEN vs. The Competition

MetricPenumbraMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$9.71B$7.03B$6.09B$21.74B
Dividend YieldN/A1.17%5.73%3.62%
P/E Ratio66.3127.3484.7532.40
Price / Sales7.6027.65519.2958.79
Price / Cash87.9421.9637.1624.37
Price / Book8.315.1512.244.59
Net Income$14.01M$179.79M$3.33B$1.01B
7 Day Performance-4.46%0.20%1.19%1.32%
1 Month Performance-3.34%1.24%6.18%-1.45%
1 Year Performance19.49%1.67%59.89%9.54%

Penumbra Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PEN
Penumbra
4.8837 of 5 stars
$249.32
-1.8%
$302.81
+21.5%
+23.3%$9.71B$1.28B66.314,500Analyst Forecast
Analyst Revision
LNTH
Lantheus
4.5342 of 5 stars
$54.59
+2.0%
$74.50
+36.5%
-51.9%$3.64B$1.53B9.84700Trending News
Analyst Revision
ITGR
Integer
3.7241 of 5 stars
$102.21
+1.1%
$139.57
+36.6%
-19.6%$3.54B$1.72B45.0311,000Upcoming Earnings
Analyst Forecast
GEHC
GE HealthCare Technologies
3.8863 of 5 stars
$71.84
+1.2%
$85.20
+18.6%
-18.5%$32.42B$19.67B15.2453,000Positive News
Analyst Forecast
PHG
Koninklijke Philips
3.9274 of 5 stars
$27.53
+0.7%
N/A-10.2%$26.32B$19.50B144.8766,678Positive News
ZBH
Zimmer Biomet
4.4337 of 5 stars
$95.13
+0.4%
$113.16
+19.0%
-2.8%$18.76B$7.68B11.9417,000
SNN
Smith & Nephew SNATS
2.9402 of 5 stars
$35.18
+0.2%
$36.00
+2.3%
+23.9%$14.99B$5.81B16.2917,349Analyst Forecast
SOLV
Solventum
2.8497 of 5 stars
$70.89
+0.5%
$84.89
+19.8%
-0.4%$12.23B$8.25B12.6122,000Positive News
STVN
Stevanato Group
1.8046 of 5 stars
€23.33
-2.2%
N/A+35.6%€7.07B€1.19B43.205,521
IRTC
iRhythm Technologies
1.4865 of 5 stars
$177.37
+0.7%
$180.23
+1.6%
+190.9%$5.66B$591.84M0.002,000Analyst Forecast
BLCO
Bausch + Lomb
1.6369 of 5 stars
$14.87
+3.8%
$15.70
+5.6%
-28.4%$5.07B$4.79B34.1013,500

Related Companies and Tools


This page (NYSE:PEN) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners